Wharton's jelly mesenchymal stem cell-derived small extracellular vesicles as natural nanoparticles to attenuate cartilage injury via microRNA regulation

Quick Facts

  • Publication title: Wharton's jelly mesenchymal stem cell-derived small extracellular vesicles as natural nanoparticles to attenuate cartilage injury via microRNA regulation
  • Journal: INT J PHARMACEUT
  • Year: 2022
  • DOI: 10.1016/j.ijpharm.2022.121952
  • PMID/PMCID: 35753534

Research overview

The main strategy of tissue repair and regeneration focuses on the application of mesenchymal stem cells and cell-based nanoparticles, but there are still multiple challenges that may have negative impacts on human safety and therapeutic efficacy. Our findings suggest that WJMSC-sEV-induced chondrogenesis is a promising innovative and feasible cell-free nanotherapy for OA treatment.

Key findings

The main strategy of tissue repair and regeneration focuses on the application of mesenchymal stem cells and cell-based nanoparticles, but there are still multiple challenges that may have negative impacts on human safety and therapeutic efficacy.

Cell-free nanotechnology can effectively overcome these obstacles and limitations.

Mesenchymal stem cell (MSC)-derived natural small extracellular vesicles (sEVs) represent ideal nanotherapeutics due to their low immunogenicity and lack of tumorigenicity.

Here, sEVs harvested from Wharton's jelly mesenchymal stem cells (WJMSCs) were identified.

Echo Biotech Role

Echo Biotech contributed EV isolation and purification, miRNA profiling/sequencing and bioinformatic analysis; the study also used or cited Exosupur®.

Related platforms: Exoomics®, Research Reagents & Tools

Related services and capabilities: EV Isolation & Purification, EV miRNA Profiling / Sequencing, Research Reagent / Product Supply

Related products or reagents: Exosupur® EV Isolation/Purification Kit

References

Original publication: Wharton's jelly mesenchymal stem cell-derived small extracellular vesicles as natural nanoparticles to attenuate cartilage injury via microRNA regulation International journal of pharmaceutics. 2022. DOI: 10.1016/j.ijpharm.2022.121952. PMID/PMCID: 35753534.